Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H20ClNO7 |
Molecular Weight | 421.828 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CC1=CC=C2OC(OC2=C1)(C(O)=O)C(O)=O)NC[C@H](O)C3=CC(Cl)=CC=C3
InChI
InChIKey=JEDJMKTVUPSHFW-ABAIWWIYSA-N
InChI=1S/C20H20ClNO7/c1-11(22-10-15(23)13-3-2-4-14(21)9-13)7-12-5-6-16-17(8-12)29-20(28-16,18(24)25)19(26)27/h2-6,8-9,11,15,22-23H,7,10H2,1H3,(H,24,25)(H,26,27)/t11-,15+/m1/s1
Molecular Formula | C20H20ClNO7 |
Molecular Weight | 421.828 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23056223Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21170122 | https://www.ncbi.nlm.nih.gov/pubmed/11311069 | https://www.ncbi.nlm.nih.gov/pubmed/26988163
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23056223
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21170122 | https://www.ncbi.nlm.nih.gov/pubmed/11311069 | https://www.ncbi.nlm.nih.gov/pubmed/26988163
CL-316243 is a selective and highly specific β3-adrenoceptor agonist. CL 316243 possesses anti-obesity and anti-diabetic effects due to increasing brown adipose tissue thermogenesis and metabolic rate, and consequently may be useful for treating obesity as well as non-insulin-dependent diabetes mellitus in obese persons, without causing excessive side effects.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL246 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21170122 |
220.0 nM [EC50] | ||
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11311069 |
262.0 µM [EC50] | ||
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11277513 |
111.0 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Is the "atypical" beta-receptor in the rat stomach fundus the rat beta 3 receptor? | 1995 Jan |
|
Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. | 1999 Apr |
|
beta(3)-adrenoceptor regulation and relaxation responses in mouse ileum. | 2000 Mar |
|
beta(1)- and beta(3)-adrenoceptor mediated smooth muscle relaxation in hypothyroid rat ileum. | 2001 Mar |
|
Beta3 adrenergic stimulation inhibits the opossum lower esophageal sphincter. | 2002 Nov |
|
Expression of glycerokinase in brown adipose tissue is stimulated by the sympathetic nervous system. | 2003 Jun |
|
The full expression of fasting-induced torpor requires beta 3-adrenergic receptor signaling. | 2006 Jan 4 |
|
The effects and selectivity of beta-adrenoceptor agonists in rat myometrium and urinary bladder. | 2007 Nov 14 |
|
Comparative effects of oleoyl-estrone and a specific beta3-adrenergic agonist (CL316, 243) on the expression of genes involved in energy metabolism of rat white adipose tissue. | 2010 Feb 25 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23056223
The daily dose for rats was 1 mg/ kg body weight for 4 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26988163
Effect of CL (CL-316243) alone or in combination with ADA, PTX or WT on PI(3,4,5)P3 production were studied using rat epididymal adipocytes. [32P]orthophosphate-labeled adipocytes that were treated or not treated with ADA (2 U/ml, 10 min) or PTX (1 μg/ml, 60 min) were incubated for 1 min with or without CL (1 μM). In addition, [32P]orthophosphate-labeled adipocytes treated with or without WT (3 μM, 1 min) were incubated for 1 min with or without CL or INS (0.7 μM). Furthermore, adipocytes treated or not treated with ADA or PTX were incubated for 10 min with or without CL. The radioactivity of PI(3,4,5)P3 (PIP3) that were separated by TLC and the accumulation of cAMP in adipocytes were determined.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:22:03 GMT 2023
by
admin
on
Sat Dec 16 10:22:03 GMT 2023
|
Record UNII |
52H8DB0TKX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
52H8DB0TKX
Created by
admin on Sat Dec 16 10:22:04 GMT 2023 , Edited by admin on Sat Dec 16 10:22:04 GMT 2023
|
PRIMARY | |||
|
5486546
Created by
admin on Sat Dec 16 10:22:04 GMT 2023 , Edited by admin on Sat Dec 16 10:22:04 GMT 2023
|
PRIMARY | |||
|
183720-02-7
Created by
admin on Sat Dec 16 10:22:04 GMT 2023 , Edited by admin on Sat Dec 16 10:22:04 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |